洛匹那韦药代动力学的研究进展 |
投稿时间:2011-12-06 修订日期:2012-01-14 点此下载全文 |
引用本文:姚亚敏,沐俊,孙骥,马芳,卢洪洲,张丽军.洛匹那韦药代动力学的研究进展[J].药学实践杂志,2012,30(5):336~339 |
摘要点击次数: 1788 |
全文下载次数: 1409 |
|
基金项目:抗艾滋病病毒新药临床评价研究技术平台建设(2012ZX09303013);成人艾滋病适宜治疗策略研究与应用(2012ZX10001003) |
|
中文摘要:洛匹那韦作为第二代蛋白酶抑制剂,在艾滋病治疗领域得到广泛应用。然而,该药能被代谢酶CYP3A4快速代谢,在临床应用中,存在较大的个体差异。因此,对洛匹那韦进行药代动力学分析,了解其血药浓度与疗效以及不良反应的关系对优化临床用药具有重要意义。本文全面综述了近年来洛匹那韦浓度分析方法、药代动力学研究进展,为日后洛匹那韦治疗药物监测以及个体化用药研究提供归纳总结材料。 |
中文关键词:洛匹那韦 艾滋病 蛋白酶抑制剂 药代动力学 |
|
Progress on pharmacokinetics of lopinavir |
|
|
Abstract:Lopinavir was widely used as a second generation protease inhibitor in AIDS therapy, which was quickly metabolized by CYP3A4. For individual variance might lead to different metabolism, it was important to study the pharmacokinetic parameters of lopinavir and learn the relationship between drug concentration and curative effect or adverse reactions. The methods for determining lopinavir concentration and the progress of pharmacokinetic research were reviewed in this paper which might offer some help for treatment drug monitoring (TDM) and personalized dosage research. |
keywords:lopinavir AIDS protease inhibitor pharmacokinetics |
查看全文 查看/发表评论 下载PDF阅读器 |
|
关闭 |
|
|
|